Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
October 03, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on Pioneering Anti-CHI3L1 Discoveries Providence, RI, Oct. 03, 2023 (GLOBE...
Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.
September 14, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Presentation will be hosted live on Ocean Biomedical’s Youtube Channel at 2:00pm ET Providence, RI, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next-generation...
Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers
August 10, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr. Jonathan Kurtis, MD, PhD on September 14, 2023 Providence, RI,...
Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis.
August 09, 2023 08:31 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr. Jonathan Kurtis, MD, PhD on September 14, 2023 Providence, RI, Aug. ...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day
August 01, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical’s Oncology Platform currently consists of 27 Patents Issued or Pending. Ocean Biomedical’s first-in-class anti-CHi3L1 therapeutic immunotherapy program has shown...
Ocean Biomedical’s (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean’s Program to Address Global and Emerging U.S. Malaria Challenges
July 11, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Multiple Patents have been received in the U.S. and Internationally for Novel Vaccine Candidate and “Whole New Class” of Malaria Therapeutics. Providence, RI, July 11, 2023 (GLOBE NEWSWIRE) --...
Ocean Biomedical, Inc. Joins the Russell 2000® Index
June 27, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical’s Inclusion in the Russell 2000® Index and Russell 3000® Index Builds Momentum for Cutting Edge Therapeutic Programs Targeting Multiple Cancers, Fibrotic Diseases, and Malaria ...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma), and Metastatic Melanoma.
June 26, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Patent broadens protection around Ocean Biomedical’s first-in-class anti-CHi3L1 antibody to include new bispecific approaches targeting immune checkpoints, with potential application in multiple...
Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Coverage by Taglich Brothers with a Share Price Target of $20.
June 01, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, June 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a new-era biopharma company working to accelerate the development and commercialization of scientifically...
Taglich Brothers Initiates Coverage of Ocean Biomedical, Inc.
May 31, 2023 09:30 ET
|
Taglich Brothers Inc
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Taglich Brothers, Inc. announces that it has initiated coverage of Ocean Biomedical, Inc. (NASDAQ: OCEA). Ocean Biomedical, Inc. headquartered in...